- Born:
- May 24, 1898, Cambridge, Mass., U.S.
- Died:
- May 20, 1986, Kennett Square, Pa. (aged 87)
- Subjects Of Study:
- congenital heart disease
- heart
- thalidomide
Helen Brooke Taussig
-
Who was Helen Brooke Taussig?
Helen Brooke Taussig (1898-1986) was an American physician who is considered the founder of pediatric cardiology. She is best known for her contributions to the creation of the first successful treatment for "blue baby" syndrome.
Taussig was persistent and determined, which defined her character. She was dyslexic as a child, and later in life, she developed hearing loss, which led her to develop a method to explore the beat of the human heart using her hands.
In 1944, Taussig and American surgeon Alfred Blalock developed the Blalock-Taussig shunt, an artery-like tube designed to deliver oxygen-rich blood from the lungs to the heart.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What field of medicine did Helen Taussig work in?
Helen Brooke Taussig was an American physician recognized as the founder of pediatric cardiology. She is best known for her contributions to the first successful treatment of "blue baby" syndrome. Taussig's work led to the development of the Blalock-Taussig shunt, an artery-like tube designed to deliver oxygen-rich blood from the lungs to the heart. In 1965, Taussig became the first woman president of the American Heart Association.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What is Helen Taussig best known for in medical history?
Helen Brooke Taussig (1898â1986) was an American physician and the founder of pediatric cardiology. She is best known for her contributions to developing the first successful treatment for "blue baby" syndrome. Taussig determined that the syndrome was caused by a lack of oxygenated blood circulating from the lungs to the heart. She championed the creation of an arterial patent ductus, or shunt, to alleviate the problem. Together with American surgeon Alfred Blalock, she developed the Blalock-Taussig shunt, an artery-like tube designed to deliver oxygen-rich blood from the lungs to the heart. The first successful surgery was performed in 1944 on a baby with tetralogy of Fallot, a congenital heart disorder that gives rise to blue baby syndrome.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What is the "blue baby syndrome," and how did Taussig help treat it?
Blue baby syndrome refers to cyanosis in infants, characterized by a bluish skin discoloration due to insufficient oxygen in the blood, often resulting from congenital heart defects.
Helen Brooke Taussig recognized a lack of oxygenated blood circulating from the lungs to the heart as the problem. With surgeon Alfred Blalock, she developed the Blalock-Taussig shunt, an artery-like tube that delivers oxygen-rich blood from the lungs to the heart. The first successful surgery using this shunt was on a baby with tetralogy of Fallot, a congenital heart disorder that causes blue baby syndrome, on November 29, 1944.
4 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
How did the Blalock-Taussig shunt surgery help heart patients?
The Blalock-Taussig shunt, developed by Helen Brooke Taussig and Alfred Blalock, was created to treat infants with tetralogy of Fallot, also known as "blue baby" syndrome. In babies with this congenital heart defect, deoxygenated venous blood shunts from the right to the left side of the heart, causing a bluish discoloration of the skin. Taussig recognized that creating a shunt could alleviate the problem by delivering oxygen-rich blood from the lungs to the heart. The Blalock-Taussig shunt is an artery-like tube that delivers oxygen-rich blood from the lungs to the heart, improving oxygen circulation and enabling patients to live nearly normal lives.
3 Britannica SourcesCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles. -
What lasting impact did Helen Taussig have on medicine and heart surgery?
Helen Brooke Taussig is recognized as the founder of pediatric cardiology. Taussig, despite being dyslexic and hard of hearing, made a lasting impact on medicine through her work on "blue baby" syndrome. She observed common beat patterns in the malformed hearts of infants, identified the lack of oxygenated blood circulating from the lungs to the heart as the problem, and reasoned that creating an arterial patent ductus, or shunt, would alleviate the problem. Together with American surgeon Alfred Blalock, she developed the Blalock-Taussig shunt, an artery-like tube designed to deliver oxygen-rich blood from the lungs to the heart. The first successful surgery was performed on an infant with tetralogy of Fallot on November 29, 1944.
1 Britannica SourceCreated from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.
Helen Brooke Taussig (born May 24, 1898, Cambridge, Mass., U.S.âdied May 20, 1986, Kennett Square, Pa.) was an American physician recognized as the founder of pediatric cardiology, best known for her contributions to the development of the first successful treatment of âblue babyâ syndrome.
Helen Taussig was born into a distinguished family as the daughter of Frank and Edith Guild Taussig. Her father was a prominent economics professor at Harvard University, and her mother was one of the first women to attend Radcliffe College (today known as the Radcliffe Institute for Advanced Study), an extension of Harvard that provided instruction for women. Although Taussig enjoyed a privileged upbringing, adversity cultivated in her a determination that later defined her character. As a child, the dyslexic Taussig laboured to become proficient in reading and was tutored by her father, who recognized the potential of her logical mind. When Taussig was 11, her mother died of tuberculosis, an illness Helen would later contract as well. However, these obstacles did not discourage Taussig from obtaining a university education. She enrolled at Radcliffe College in 1917, transferring to the University of California, Berkeley, in 1919, where she earned an A.B. in 1921. Taussig aspired to study medicine at Harvard but was denied admission because the university did not accept women into its academic degree program. Instead, she attended the Boston University School of Medicine from 1922 to 1924 and graduated from the Johns Hopkins University School of Medicine in 1927.
Two individuals had a far-reaching impact on Taussigâs career. First was Canadian pathologist Maude Abbott of McGill University in Montreal. Abbott was a strong-minded role model whose earlier studies of congenital heart disease created the foundation for Taussigâs own research into heart disease. Then, while an intern at Johns Hopkins, Taussigâs work attracted the attention of American pediatrician Edwards A. Park, the director and, later, the chief of pediatrics at Johns Hopkins. In 1930 Park elevated Taussig to director of Hopkinsâ Harriet Lane Clinic, a health care centre for children, making her one of the first women in the country to hold such a prestigious position.
Taussigâs career advanced, but her personal challenges mounted. In her 30s she grew deaf, and as a result she developed an innovative method to explore the beat of the human heart using her hands to compensate for her hearing loss. Relying on this method, Taussig noticed common beat patterns in the malformed hearts of infant patients who outwardly displayed a cyanotic hue and hence were known as âblue babies.â She traced the root of the problem to a lack of oxygenated blood circulating from the lungs to the heart. Taussig reasoned that the creation of an arterial patent ductus, or shunt, would alleviate the problem, and she championed the cause before American surgeon Alfred Blalock, Hopkinsâ chief of the department of surgery. Together they developed the Blalock-Taussig shunt, an artery-like tube designed to deliver oxygen-rich blood from the lungs to the heart. On November 29, 1944, Eileen Saxton, an infant affected by tetralogy of Fallot, a congenital heart disorder that gives rise to blue baby syndrome and that was previously considered untreatable, became the first patient to survive a successfully implanted Blalock-Taussig shunt. The miracle surgery was touted in the American magazines Time and Life, as well as in newspapers around the world. Later, American laboratory technician Vivien Thomas was also recognized for his contributions to the surgery.
Taussig was a prolific writer, publishing an astounding number of medical papers. In 1947 she wrote Congenital Malformations of the Heart, which was revised in 1960. Throughout her lifetime she received worldwide honours. She was awarded the Medal of Freedom by U.S. President Lyndon B. Johnson in 1964, and in 1965 Taussig became the first woman president of the American Heart Association. In addition, Taussig testified before the U.S. Congress about the harmful effects of the drug thalidomide, which had produced deformed children in Europe.
Taussigâs ideas and determination have had long-lasting impacts on cardiology. Physicians originally believed the early blue babies could possibly endure a 40-year life span. At the turn of the 21st century, some of these early patients continued to survive into their sixth decade.